XORTX Therapeutics Announces Closing of US$12 Million Public Offering

Rhea-AI Summary

XORTX Therapeutics announced the successful closing of a public offering on October 15, 2021, raising approximately US$12 million through the sale of 2,906,000 units, each consisting of one common share and one warrant with an exercise price of US$4.77. The offering has positioned the company for strategic advancement in its clinical programs, particularly for products targeting progressive kidney disease. The company also granted underwriters a 45-day option for additional shares, enhancing liquidity.

Positive

• Raised approximately US$12 million from public offering, providing strong cash position.
• Warrants exercise has already brought in over CAD$1 million, further strengthening finances.
• Funds will support advancement of clinical trials for XRx-008 and XRx-101.

Negative

• None.

CALGARY, Alberta, Oct. 15, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, today announced the closing of an underwritten public offering of 2,906,000 units ("Units"), with each Unit consisting of one common share, no par value, and one warrant ("Warrant") to purchase one common share at a public offering price of US$4.13 per Unit, for aggregate gross proceeds of approximately US$12 million, prior to deducting underwriting discounts and other offering expenses (the “Offering”). The common shares and warrants contained in the Units are immediately separable upon issuance. The warrants have an initial exercise price of US$4.77 per share, are immediately exercisable, and have a term of approximately five years. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 435,900 common shares and/or warrants to purchase up to an additional 435,900 common shares at the Offering price less the underwriting discounts. On October 15, 2021, A.G.P. exercised its option to purchase additional warrants to purchase up to an additional 435,900 common shares.

A.G.P. / Alliance Global Partners acted as sole book-running manager for the Offering.

Dr. Allen Davidoff, President and CEO stated, “We wish to thank the team at Alliance Global Partners for this successful offering and to welcome our new shareholders.  This financing, along with recent warrant exercises that have brought in over $1 million (Canadian dollars), places XORTX in a strong cash position to continue to advance our clinical trial programs and regulatory filings in support of our proprietary formulations - XRx-008 and XRx-101.”

The offering was made pursuant to an effective registration statement on Form F-1 (Registration No. 333-258741) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A final prospectus relating to this offering was filed with the SEC. Copies of the final prospectus relating to the offering may be obtained by contacting A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by email at prospectus@allianceg.com. Investors may also obtain these documents at no cost by visiting the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.

For further information, please contact:
Allen Davidoff, CEO	Nick Rigopulos, Director of Communications
adavidoff@xortx.com or +1 403 455 7727	nick@alpineequityadv.com or +1 617 901 0785
Dr. David Sans, Head of Corporate Development in New York City
dsans123@xortx.com or +1 347 573 0541

The CSE and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Important Information

No announcements or information regarding the Offering may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose. No steps have been, or will be taken for the Offering of securities in any jurisdiction where such steps would be required. The issue or sale of securities, and the subscription for or purchase of shares or securities are subject to special legal or statutory restrictions in certain jurisdictions. XORTX is not liable if these restrictions are not complied with by any other person.

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's website, www.sec.gov.

FAQ

What details were included in XORTX's public offering announced on October 15, 2021?

XORTX's public offering consisted of 2,906,000 units, priced at US$4.13 per unit, raising approximately US$12 million.

How will the funds from the offering impact XORTX Therapeutics?

The funds will enhance XORTX's cash position to advance its clinical trial programs and regulatory filings.

What is the term and exercise price of the warrants included in the offering?

The warrants have an initial exercise price of US$4.77 per share, are immediately exercisable, and have a term of approximately five years.

Who acted as the book-running manager for XORTX's offering?

A.G.P. / Alliance Global Partners acted as the sole book-running manager for the offering.

What is the purpose of the underwriters' 45-day option in the offering?

The underwriters have a 45-day option to purchase up to an additional 435,900 common shares and/or warrants to strengthen the offering further.